|
uk biobank |
11 |
|
mendelian randomization |
10 |
|
coronary heart disease |
8 |
|
genetic susceptibility |
7 |
|
adolescents |
6 |
|
drug-target mendelian randomization |
6 |
|
genetic risk |
6 |
|
hmgcr inhibitors |
6 |
|
metformin |
6 |
|
pcsk9 inhibitors |
6 |
|
safety |
6 |
|
alzheimer’s disease |
5 |
|
dementia |
5 |
|
hypertension |
5 |
|
mendelian randomisation |
5 |
|
mendelian randomization analysis |
5 |
|
active transport |
4 |
|
ampk |
4 |
|
cancer |
4 |
|
coronary artery disease |
4 |
|
covid-19 |
4 |
|
metformin targets |
4 |
|
abdominal obesity |
3 |
|
ace2 |
3 |
|
blood pressure |
3 |
|
cardiometabolic risk markers |
3 |
|
cardiovascular disease |
3 |
|
cardiovascular risk factor |
3 |
|
causal inference |
3 |
|
computer use |
3 |
|
disease aetiology |
3 |
|
ferritin |
3 |
|
fgf23 |
3 |
|
genetic epidemiology |
3 |
|
genetics |
3 |
|
glycaemic traits |
3 |
|
glycated hemoglobin |
3 |
|
glycemic traits |
3 |
|
grip strength |
3 |
|
growth differentiation factor 15 |
3 |
|
hba1c |
3 |
|
healthy lifestyle |
3 |
|
hemoglobin |
3 |
|
hepcidin |
3 |
|
insulin |
3 |
|
iron |
3 |
|
kidney disease |
3 |
|
lifestyle |
3 |
|
linearity |
3 |
|
liver cirrhosis |
3 |
|
liver iron |
3 |
|
liver steatosis |
3 |
|
longevity |
3 |
|
mediation |
3 |
|
mendelian randomization studies |
3 |
|
older adults |
3 |
|
physical activity |
3 |
|
polygenic risk scores |
3 |
|
random allocation |
3 |
|
randomization mr |
3 |
|
sedentary behavior |
3 |
|
sex hormones |
3 |
|
stroke |
3 |
|
systematic review |
3 |
|
testosterone |
3 |
|
tv viewing |
3 |
|
type 2 diabetes |
3 |
|
type 2 diabetes mellitus |
3 |
|
venous thromboembolism |
3 |
|
adamts-13 |
2 |
|
brain expression |
2 |
|
cardiometabolic diseases |
2 |
|
chronic diseases |
2 |
|
cognitive function |
2 |
|
diabetes mellitus |
2 |
|
general population |
2 |
|
ischemic heart disease |
2 |
|
lipids |
2 |
|
liver - physiology - china - guangzhou |
2 |
|
mitochondrial function |
2 |
|
non-diabetic individuals |
2 |
|
smoking - china - guangzhou |
2 |
